Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2018 | CMV treatment for stem cell transplant recipients: antivirals

Genovefa Papanicolaou • 18 Mar 2018
EBMT 2018
General Foscarnet Ganciclovir Letermovir Maribavir Valganciclovir

Many infections can occur in cancer patients who are immunocompromised after receiving a stem cell transplant. In this interview, Genovefa Papanicolaou, MD, from Memorial Sloan Kettering Cancer Center, New York, NY, speaks about the current and future developments in the treatment of a particularly dangerous viral infection, cytomegalovirus (CMV). This interview was conducted at the 2018 European Group for Blood and Marrow Transplantation (EBMT) Annual Meeting, held in Lisbon, Portugal.

More from Genovefa Papanicolaou

Vaccines for the treatment of CMV in stem cell transplant recipients
1:06
Vaccines for the treatment of CMV in stem cell transplant recipients
Genovefa Papanicolaou • 18 Mar 2018
Preventing cytomegalovirus (CMV) infections in patients receiving bone marrow transplants
1:07
Preventing cytomegalovirus (CMV) infections in patients receiving bone marrow transplants
Genovefa Papanicolaou • 2 Dec 2016

Related Videos

The ethical challenges of AI in hematology: patient communication, trust and regulation
3:12
The ethical challenges of AI in hematology: patient communication, trust and regulation
Adrián Mosquera Orgueira • 24 Sep 2026
The future of AI in hematology: personalized medicine, opportunities and risks
2:30
The future of AI in hematology: personalized medicine, opportunities and risks
Adrián Mosquera Orgueira • 24 Sep 2026
The multi-system impacts of CHIP and its link to subspecialties within internal medicine
5:18
The multi-system impacts of CHIP and its link to subspecialties within internal medicine
Shyam Patel • 13 Oct 2026
The scientific and clinical implications of therapy-related CHIP in oncology
2:43
The scientific and clinical implications of therapy-related CHIP in oncology
Shyam Patel • 13 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals